Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: TobagoJack who wrote (157608)	5/9/2020 7:21:50 AM
From: Julius Wong	Respond to of 217549

For Coronavirus treatment and vaccine, I like Biosig Technologies, Inc. (BSGM). ViralClear Pharmaceuticals, is part of NeuroClear, itself a subsidiary of Westport, Connecticut-based BioSig Technologies. ViralClear has Vicromax(tm) (merimepodib). Mayo Clinic Preparing to Commence Phase II FDA Clinical Trial for the Treatment of COVID-19 with Vicromax™ ir.biosig.com ****** I also like Sorrento Therapeutics (SRNE) SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES finance.yahoo.com Analyst Impressed by Sorrento’s COVID-19 Pipeline, Says ‘Buy’ finance.yahoo.com SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS finance.yahoo.com * Sorrento owns 25% of Celularity. Sorrento Therapeutics and Mount Sinai join forces to develop Covid-19 antibody shield cnbc.com